Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEL-SCI Corporation Gets Russia OK For Multikine Trial, Shares Up More Than 4% 09/28 08:26 AM
08:26 AM Eastern Daylight Time, 09/28/2010 (MidnightTrader) -- CEL-SCI Corporation (CVM:$0.7475,$0.0000,0.00%) says it received approval from the Ethical Council Affiliated with the Ministry of Healthcare and Social Development of the Russian Federation for the Phase III clinical trial of Multikine, an immunotherapy developed as a first-line standard of care in treating head and neck cancer.
CVM says it expects to have three clinical centers in Russia, out of an expected forty-eight clinical centers world-wide.
Price: .78, Change: +.0325, Percent Change: +4.35
http://www.midnighttrader.com
Get more news on:SYMBOLS: CVMNEWS TYPE: Pre-Market Movers, Extended TradingSECTORS: Pharmaceuticals, Health Care
Visteon's 'C-Beyond' Vehicle Concept To Be Showcased at Paris Motor Show - A New Vision for Connected and Sustainable Mobility
Global automotive supplier highlights more than 40 innovative technologies and concepts at the Estech exhibit in Hall 3, Stand 334 09/27 11:00 AM
PARIS, Sept. 27, 2010 /PRNewswire/ -- Visteon Corporation (VSTNQ:$0.5500,$0.0349,6.78%) is displaying the successful C-Beyond vehicle concept, featuring its unique range of innovative technologies, at the 2010 Paris Motor Show. The C-Beyond is on display for the first time publicly at the Estech stand. Visteon (VSTNQ:$0.5500,$0.0349,6.78%) partnered with Estech, a service and styling bureau, to execute the design and integrate Visteon (VSTNQ:$0.5500,$0.0349,6.78%) products and concepts into the demonstration vehicle. Â
Featuring more than 40 innovative technologies in climate and interior systems, infotainment and connectivity, and exterior lighting, the C-Beyond has received enthusiastic reviews from vehicle manufacturers and automotive media throughout Europe, Japan and China. It is scheduled to be shown in North America starting in early 2011.
"We are delighted with the positive responses from our customers that confirm our new technology concepts address future consumer trends and needs," said Steve Meszaros, Visteon (VSTNQ:$0.5500,$0.0349,6.78%) product group president. "These concepts are designed to inspire vehicle manufacturers to 'see beyond' the conventional role of the vehicle to create an innovative user experience enabled by Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's technology and advanced development."
The C-Beyond, developed on a C-segment vehicle body, represents Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's vision of how seamless connectivity and sustainable mobility may influence the way consumers use and interact with the next generation of vehicles. Using Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's proprietary research methodologies, the C-Beyond incorporates insights gathered from consumers and vehicle manufacturers around the world.
C-Beyond is a testament to Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's core strengths of in-vehicle technology integration and optimizing human-machine interface (HMI). In addition, enhanced personalization and individual comfort features for all occupants promote new ways of enjoying and connecting to the vehicle.
The technologies demonstrated in the C-Beyond are at different stages of development, ranging from concepts to commercialization-ready. They include:
Advanced connectivity − The C-Beyond evolves traditional cockpit electronics from a driver information function to "driver coaching," and uses connectivity features for remote or on-board configuration, advanced navigation with pre-journey planning, and real-time traffic updates.
Also featured is Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's infotainment and Internet platform, a scalable solution with audio, consumer device connectivity, media manager, navigation, rear seat infotainment and voice control.
Personal comfort features − The C-Beyond introduces Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's vertical air flow concept that creates four discrete, vertical air flow zones. The roof-mounted registers direct air flow from ceiling-to-floor within the occupants' personal zone for fully customized comfort and temperature control, compared with traditional front-to-rear cabin air flow. Visteon's adaptive climate controls automatically adjust to the number and location of occupants, and save energy by deactivating in unoccupied zones. Vertical air flow eliminates traditional instrument panel registers, thus freeing significant packaging space in the cockpit area to allow for additional styling options. This concept is suitable for both electric and conventional vehicles and does not require architectural changes to the HVAC module.
Interior ambience − The C-Beyond exhibits a high level of perceived quality with simple designs and a visibly lighter instrument panel architecture. By redistributing traditional interior elements − including dedicated controls, storage, comfort and air distribution features − these concepts allow passengers to create their own personal zones. Ample use of ambient lighting creates a comfortable space for all occupants.
Exterior and lighting features − The C-Beyond is equipped with Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's proprietary high-intensity headlamp LED projector modulethat provides all main beam patterns. Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's camera-driven, adaptive high-beam system switches automatically between high and low beams according to the flow of passing and oncoming traffic. In addition, the system offers a glare-free mode that enables the lamps to continuously operate in high-beam mode with programmable shutters that reduce the light pattern for oncoming vehicles.
For more information about Visteon (VSTNQ:$0.5500,$0.0349,6.78%) 's C-Beyond concept, visit: www.visteon.com/innovate
Based in Paris, Estech specializes in developing industrial design projects.
Visteon Corporation (VSTNQ:$0.5500,$0.0349,6.78%) is a leading global automotive supplier that designs, engineers and manufactures innovative climate, interior, electronic and lighting products for vehicle manufacturers. With corporate offices in Van Buren Township, Mich. (U.S.); Shanghai, China; and Chelmsford, UK; the company has facilities in 25 countries and employs approximately 26,000 people.
SOURCE Visteon Corporation (VSTNQ:$0.5500,$0.0349,6.78%)
Get more news on:SYMBOLS: VSTNQNEWS TYPE: SECTORS: Automobiles, Consumer Discretionary, Capital Markets, Financials
Implant Sciences Signs Beijing Ritchie Link Technology as Service Provider for QS-H150 in China 09/27 10:42 AM
Implant Committed to Superior After-Sales Service in China and Other International Markets 09/27 10:42 AM
WILMINGTON, MA -- (MARKET WIRE) -- 09/27/10 -- Implant Sciences Corporation (IMSC:$0.3000,$0.0000,0.00%) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that it has signed an agreement for Beijing Ritchie Link Technology to act as its service provider for the company's growing installed base of QS-H150 Quantum Sniffers? in the Chinese market.
Beijing Ritchie Link Technology is a leading service provider and distributor of security and safety equipment in China. Established in 1997, and located at Zhongguan Cun, in the Haidian District of Beijing, China's 'Silicon Valley,' Beijing Ritchie has a team of engineers trained in servicing the QS-H150. The company provides security and safety equipment to the police and other law enforcement agencies of the government in China. Beijing Ritchie Link has been distributing Implant Sciences (IMSC:$0.3000,$0.0000,0.00%) products since 2005.The service center will provide warranty and non-warranty service, repairs, maintenance and training for Implant's base of over 700 QS-H150 units in China.
"As we continue to expand our market share in China and grow our installed base of units, we want our customers to receive the best in local service, training and maintenance for their QS-H150 units. We are committed to a long-term and increased presence in our international markets. We stand out above other companies that do not provide readily accessible service and support," stated Implant Sciences (IMSC:$0.3000,$0.0000,0.00%) CEO Glenn Bolduc.
Bruce Bower, Implant Sciences Sr. Vice President, added, "This service center serves as a model for how we intend to solidify our market leading position in other high-growth markets throughout the world. The Quantum Sniffer outperforms competing technologies on the field. We also fully intend to continue to outperform in terms of service and support globally."
Beijing Ritchie Link Technology's General Manager, Dr. Zhongmou Ju commented, "The Quantum Sniffer is the top choice in security inspection equipment with Chinese police and transportation agencies due to its superior quality, performance, and reliability. We are pleased to represent and service this high-end, high-performance instrument."
About the Quantum Sniffer QS-H150
The QS-H150 Quantum Sniffer is a hand-held explosive trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.
About Implant Sciences (IMSC:$0.3000,$0.0000,0.00%)
Implant Sciences (IMSC:$0.3000,$0.0000,0.00%) develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Implant Sciences Corporation (IMSC:$0.3000,$0.0000,0.00%)
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Get more news on:SYMBOLS: IMSCNEWS TYPE: SECTORS: Electronic Equipment and Instruments, Information Technology, Electrical Equipment, Industrials
CEL-SCI Expects To Have 3 Clinical Centers In Russia
09/27 09:02 AM
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)
09-27-100902ET
Copyright (c) 2010 Dow Jones & Company, Inc.
Get more news on:SYMBOLS: CVMNEWS TYPE: SECTORS: Health Care
CEL-SCI Corporation Receives Russian Federation Ethical Council Approval for Multikine Phase III Clinical Trial in Head and Neck Cancer 09/27 09:00 AM
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (CVM:$0.695,0$-0.045000,-6.08%) announced today it has received approval from the Ethical Council Affiliated with the Ministry of Healthcare and Social Development of the Russian Federation (“Ethical Council”) for the Phase III clinical trial of Multikine®, the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. CEL-SCI (CVM:$0.695,0$-0.045000,-6.08%) expects to have three clinical centers in Russia, out of an expected forty-eight clinical centers world-wide. Head and neck cancer is a major cancer in Russia.
CEL-SCI’s Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. North Mississippi Health Services was the first site in the United States to approve enrollment of subjects.
CEL-SCI’s trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted.
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects’ tumors before the start of standard therapy. Follow-up studies of subjects enrolled in Phase II trials showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration gave clearance for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
About CEL-SCI Corporation (CVM:$0.695,0$-0.045000,-6.08%)
CEL-SCI Corporation (CVM:$0.695,0$-0.045000,-6.08%) is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery.
CEL-SCI (CVM:$0.695,0$-0.045000,-6.08%) is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI (CVM:$0.695,0$-0.045000,-6.08%) scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Source: CEL-SCI Corporation (CVM:$0.695,0$-0.045000,-6.08%)
Get more news on:SYMBOLS: CVMNEWS TYPE: SECTORS: Pharmaceuticals, Health Care
Seems a Done deal ?
YRC Worldwide, Teamsters Reach Tentative Agreement 09/24 05:26 PM
DOW JONES NEWSWIRES
YRC Worldwide Inc. (YRCW:$0.2695,$0.0045,1.70%) said it reached a tentative agreement with the International Brotherhood of Teamsters "to address the company's competitiveness, re-entry into multi-employer pension funds and progress toward long-term growth."
Shares shot up 22% to 33 cents in after-hours trading. The stock was down 68% this year as of the close.
The struggling trucking company said details of the agreement will be available after expected approval by union leadership committees and its board next week. The deal also required ratification by YRCW employees represented by the Teamsters; that is expected late next month.
Mike Smid, President-YRC and Chief Operations Officer of YRC Worldwide (YRCW:$0.2695,$0.0045,1.70%) , called the tentative agreement "an important step toward the completion of our comprehensive recovery plan."
Earlier this month, the union said it would back new employee concessions only if the effort "supports a comprehensive restructuring." The union also had said it would agree to submit recent YRC cost-saving proposals for ratification by members only "if certain conditions are met" by the company. It didn't specify those conditions.
Debt-wracked YRC has won substantial concessions over the past two years--from employees and lenders--amid dramatic efforts to stay afloat. Among them, it was able to defer about $155 million in pension obligations, as well as avoid paying an additional $300 million or so entirely.
-By Kathy Shwiff, Dow Jones Newswires; 212-416-2357; Kathy.Shwiff@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=6uN7NCETTjhKngHQfUrJmg%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
09-24-101726ET
Copyright (c) 2010 Dow Jones & Company, Inc.
Get more news on:SYMBOLS: YRCWNEWS TYPE: SECTORS: Road and Rail, Industrials
Genta Initiates New Trial of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Bladder Cancer
09/24 09:00 AM
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)-- Genta Incorporated (GETA:$0.55,00$-0.07,00-11.29%) today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development.
The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.
The new study will examine the efficacy and safety of tesetaxel in patients with advanced bladder cancer who have developed progressive disease after treatment with a single 1st-line regimen. The 1st-line regimen is expected to be a combination of cisplatin plus gemcitabine (Gemzar®; Eli Lilly, Inc.).
The primary endpoint of this study is overall response rate. Secondary endpoints include durable response, disease control, progression-free survival, and safety. The dose for the new trial was determined from Genta’s ongoing studies in patients with advanced gastric cancer and advanced melanoma.
Patients who progress on 1st-line treatment for invasive bladder cancer have a poor prognosis, and toxicity is an important issue in clinical care. Compared with standard taxanes, clinical and preclinical data show that tesetaxel:
Eliminates serious (occasional fatal) hypersensitivity reactions
Eliminates requirements for premedication (e.g., steroids, antihistamines, etc.)
Reduces damage to peripheral nerves
Is not cross-resistant with standard taxanes
Offers flexible and convenient dosing for patients
“Standard taxanes are active in bladder cancer, but as yet none has received regulatory approvalâ€, said Dr. Raymond P. Warrell, Jr., Genta’s Chairman and Chief Executive Officer. “Recently, two large companies terminated their programs with potentially competitive agents in this indication. Thus, an important unmet need has opened for a highly active agent that may reduce side effects. Having observed preliminary activity in Phase 1, we wish to swiftly clarify the potential activity of tesetaxel in this disease that, if confirmed, could lead to registration-directed clinical trials.â€
About Bladder Cancer
According to the American Cancer Society, approximately 314,000 new cases of bladder cancer are diagnosed each year, which annually results in the death of 124,000 individuals. In the U.S., annual deaths from bladder cancer are approximately one-half the number of deaths due to prostate cancer. Agents approved or commonly used for 1st-line use in advanced bladder cancer include methotrexate, cisplatin, doxorubicin, mitomycin, and gemcitabine. There is no standard of care, nor are any agents approved in the U.S., for patients whose disease has progressed disease after 1st-line chemotherapy.
About Tesetaxel
Taxanes (including paclitaxel and docetaxel) are the most widely used chemotherapy drug class in cancer medicine. However, these agents are associated with serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).
Tesetaxel is a novel taxane that is administered by mouth as a capsule. The drug was developed with a goal of maintaining high antitumor activity while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables the development of novel schedules that may expand dosing options when tesetaxel is combined with other anticancer drugs (such as “all oral†chemotherapy programs). In experimental models, tesetaxel has demonstrated high activity against tumors that are resistant to paclitaxel and docetaxel.
About Genta (GETA:$0.55,00$-0.07,00-11.29%)
Genta (GETA:$0.55,00$-0.07,00-11.29%) Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has been evaluated in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials. The Company has announced that gastric (stomach) cancer will be the lead indication for Phase 3 registration studies. Genasense® (oblimersen sodium) Injection is a modified DNA-based antisense drug that may enhance the effectiveness of anticancer therapy. Genta (GETA:$0.55,00$-0.07,00-11.29%) has completed enrollment in a randomized, double-blind Phase 3 study of Genasense® in patients with advanced melanoma, known as “AGENDAâ€. Final data on survival and durable response from AGENDA, which may be pivotal for regulatory approval, are expected in the first half of 2011. Genta (GETA:$0.55,00$-0.07,00-11.29%) is exclusively marketing Ganite® (gallium nitrate injection) in the U.S., which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite® that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite® and Genasense® are available on a “named-patient†basis in countries outside the United States. For more information about Genta (GETA:$0.55,00$-0.07,00-11.29%) , please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta (GETA:$0.55,00$-0.07,00-11.29%) Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact.The words “potentiallyâ€, “anticipateâ€, “couldâ€, “calls forâ€, and similar expressions also identify forward-looking statements.The Company does not undertake to update any forward-looking statements.Factors that could affect actual results include, without limitation, risks associated with:
the Company’s ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
the safety and efficacy of the Company’s products or product candidates;
the commencement and completion of any clinical trials;
the Company’s assessment of its clinical trials;
the Company’s ability to develop, manufacture, license, or sell its products or product candidates;
the Company’s ability to enter into and successfully execute any license and collaborative agreements;
the adequacy of the Company’s capital resources and cash flow projections, or the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks to the Company’s Business as described in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially.For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2009 and its most recent quarterly report on Form 10-Q.
Source: Genta Incorporated (GETA:$0.55,00$-0.07,00-11.29%)
Get more news on:SYMBOLS: GETANEWS TYPE: Top Stories: Investing, Top NewsSECTORS: Pharmaceuticals, Health Care Providers and Services, Health Care
AbitibiBowater CCAA Plan of Reorganization Sanctioned by Quebec Superior Court 09/23 05:16 PM
ABWTQ (OTC)
MONTREAL, Sept. 23 /PRNewswire-FirstCall/ - AbitibiBowater (ABWTQ:$0.0150,$0.0000,0.00%) is pleased to announce that the Quebec Superior Court today rendered an order sanctioning the Company's plan of reorganization under the Canadian Companies' Creditors Arrangement Act (CCAA). As previously announced, on September 14 and 21, 2010, respectively, the Company received approvals for its plans of reorganization from affected creditors under the CCAA in Canada and chapter 11 of the U.S. Bankruptcy Code in the United States, except with respect to Bowater Canada Finance Corporation (BCFC), a special purpose company subsidiary with no operating assets, which has been excluded from the Company's plans of reorganization.
"We are pleased to have received an order from the Quebec Superior Court sanctioning our CCAA plan," stated David J. Paterson, President and Chief Executive Officer. "The rendering of this court order represents a major milestone in the successful restructuring of our Company."
The confirmation hearing under the Chapter 11 process is scheduled to start on September 24, 2010, in the U.S. Bankruptcy Court in Delaware. Subject to the satisfaction of certain conditions provided for in the plans of reorganization, AbitibiBowater (ABWTQ:$0.0150,$0.0000,0.00%) continues to expect emergence from creditor protection this fall.
The sanction order rendered by the Quebec Superior Court on the CCAA reorganization plan will be available through www.abitibibowater.com/restructuring.
AbitibiBowater (ABWTQ:$0.0150,$0.0000,0.00%) produces a wide range of newsprint, commercial printing and packaging papers, market pulp and wood products. It is the eighth largest publicly traded pulp and paper manufacturer in the world. AbitibiBowater (ABWTQ:$0.0150,$0.0000,0.00%) owns or operates 19 pulp and paper facilities and 24 wood products facilities located in the United States, Canada and South Korea. Marketing its products in more than 70 countries, the Company is also among the world's largest recyclers of old newspapers and magazines, and has third-party certified 100% of its managed woodlands to sustainable forest management standards. AbitibiBowater (ABWTQ:$0.0150,$0.0000,0.00%) 's shares trade over-the-counter on the Pink Sheets and on the OTC Bulletin Board under the stock symbol ABWTQ.
SOURCE ABITIBIBOWATER INC. (ABWTQ:$0.0150,$0.0000,0.00%) - ENGLISH
Get more news on:SYMBOLS: ABWTQNEWS TYPE: Corporate EventsSECTORS: Paper and Forest Products, Materials
AbitibiBowater Plans of Reorganization Approved by Creditors 09/21 12:54 PM
ABWTQ (OTC)
MONTREAL, Sept. 21 /PRNewswire-FirstCall/ - AbitibiBowater (ABWTQ:$0.0220,$-0.0065,-22.81%) is pleased to announce that the Company has received the necessary creditor approval for its plan of reorganization under chapter 11 of the U.S. Bankruptcy Code, except with respect to Bowater Canada Finance Corporation (BCFC), a special purpose company subsidiary with no operating assets, which has been excluded from the chapter 11 plan. The chapter 11 plan of reorganization received overwhelming support from creditors, both in dollar amount of claims and in number of claim holders who voted on the plan.
Having obtained the requisite votes from creditors, except with respect to BCFC, the Company and its subsidiaries will exclude BCFC from the process and proceed with plan confirmation. The Company does not believe that the exclusion of BCFC will affect the timing of its confirmation hearing that is scheduled to start on September 24, 2010, in the U.S. Bankruptcy Court in Delaware.
"We are pleased to have received approval by the vast majority of creditors under the U.S. Bankruptcy Code for our chapter 11 plan of reorganization," stated David J. Paterson, President and Chief Executive Officer. "We appreciate the support for our plans of reorganization as we work to create a more sustainable and competitive organization."
As previously announced, on September 14, 2010, the Company received approval for its plan of reorganization from affected creditors under the Canadian Companies' Creditors Arrangement Act in Canada, except with respect to BCFC.
Subject to the satisfaction of certain conditions provided for in the plans of reorganization, AbitibiBowater (ABWTQ:$0.0220,$-0.0065,-22.81%) continues to expect emergence from creditor protection this fall.
Details of the voting results under the chapter 11 plan of reorganization, including votes on a class-by-class basis, will be available through www.abitibibowater.com/restructuring.
AbitibiBowater (ABWTQ:$0.0220,$-0.0065,-22.81%) produces a wide range of newsprint, commercial printing and packaging papers, market pulp and wood products. It is the eighth largest publicly traded pulp and paper manufacturer in the world. AbitibiBowater (ABWTQ:$0.0220,$-0.0065,-22.81%) owns or operates 19 pulp and paper facilities and 24 wood products facilities located in the United States, Canada and South Korea. Marketing its products in more than 70 countries, the Company is also among the world's largest recyclers of old newspapers and magazines, and has third-party certified 100% of its managed woodlands to sustainable forest management standards. AbitibiBowater (ABWTQ:$0.0220,$-0.0065,-22.81%) 's shares trade over-the-counter on the Pink Sheets and on the OTC Bulletin Board under the stock symbol ABWTQ.
SOURCE ABITIBIBOWATER INC. (ABWTQ:$0.0220,$-0.0065,-22.81%) - ENGLISH
Get more news on:SYMBOLS: ABWTQNEWS TYPE: SECTORS:
Implant Sciences Concludes Successful Trade Mission to India
India Expected to Spend $10 Billion on Police Force Modernization and Explosives Detection in the Next Decade
09/15 08:00 AM
WILMINGTON, MA -- (MARKET WIRE) -- 09/15/10 -- Implant Sciences Corporation (IMSC:$0.3500,$0.0000,0.00%) , a high technology supplier of systems and sensors for homeland security markets, today announced that it has successfully concluded an executive trade mission to India, hosted by the U.S. Chamber of Commerce. Implant Sciences (IMSC:$0.3500,$0.0000,0.00%) has already made $6 million in sales to India prior to this trade mission and seeks to further expand sales into this critical and growing market.
Implant Sciences (IMSC:$0.3500,$0.0000,0.00%) was one of a select few companies, and the only micro-cap company, invited to participate in the mission, based on the company's success selling its QS-H150? handheld explosive trace detectors to defense and law enforcement agencies throughout India.
The delegation met with leaders of India's homeland security and defense agencies, including the National Security Advisor, the Foreign Secretary, the Director General of the Indian Coast Guard, the Director General of the Central Reserve Police Force, and others.
In attendance from Implant Sciences (IMSC:$0.3500,$0.0000,0.00%) were Glenn D. Bolduc, CEO, and Robert Liscouski, a member of the company's board of directors. Mr. Liscouski is also a Partner at Secure Strategy Group, a security advisory firm in New York City. Mr. Liscouski was appointed by President Bush as the first Assistant Secretary for Infrastructure Protection when the Department of Homeland Security was founded in 2003.
Glenn Bolduc, CEO of Implant Sciences (IMSC:$0.3500,$0.0000,0.00%) , commented, "We are extremely pleased to have been invited to this trade mission and to have participated in meetings with ministers and officials at the highest levels of security and defense in the Indian government. We believe our explosive trace detection technology is the best in the world and will contribute towards enhancing the security of India and its citizens."
In a joint statement, Secretary of State Clinton and Foreign Minister Krishna stated their shared goal of advancing security and stability across Asia through "an open, balanced, and inclusive architecture of cooperation in the region." This statement was issued in a June meeting leading up to this trade mission, in anticipation of President Obama's highly anticipated November meeting in India with Prime Minister Manmohan Singh.
Admiral James Loy, Co-Chair of the U.S. delegation, commented, "We are pleased to have participated in this mission to India in support of the U.S. government's initiatives to assist the Indian government in its homeland security efforts and its fight against terrorism. We chose the companies, including Implant Sciences (IMSC:$0.3500,$0.0000,0.00%) , which represent the best technologies the United States has developed post 9/11, to join this trade mission, to work with our Indian partners."
Admiral Loy, who led the trade mission, is Senior Counselor for The Cohen Group and former Deputy Secretary at DHS. Prior to that, Admiral Loy was the TSA Administrator and Commandant of the Coast Guard on 9/11.
"Washington and New Delhi share a common interest in defending against terrorist networks, preventing cyber attacks and protecting critical infrastructure. We had fruitful discussions this week with the government of India and the private sector, discussing collaboration and best practices in homeland security, including the products offered by Implant Sciences (IMSC:$0.3500,$0.0000,0.00%) . We have reaffirmed our partnership with India," said Co-Chair Lt. General Harry Raduege.
Lt. General Raduege, who co-led the trade mission, is Chairman of the Deloitte Center for Cyber Innovation and was previously Manager of the National Communication System during 9/11. General Raduege also led efforts to restore communications to the Pentagon and prioritized the restoration of communications in New York City following the September 11 terrorist attacks; upgraded presidential communications; and led the successful expansion of the department's Global Information Grid through a $1 billion transformational communications program.
Implant Sciences' (IMSC:$0.3500,$0.0000,0.00%) Board Member, Mr. Liscouski, concluded, "We are delighted with Implant Sciences' (IMSC:$0.3500,$0.0000,0.00%) penetration of India's homeland defense market, the fit of the company's products, and the many opportunities available to the company in this rapidly developing economy."
In the aftermath of the November 2008 attacks in Mumbai, the government of India has embarked on an ambitious plan to modernize and upgrade its homeland security apparatus including further integration of explosives detection equipment. The homeland security budget has been growing at an annual rate of 25% to fund the planned improvements in police and paramilitary forces, secure urban centers against terrorism and create a safe economic environment for the country as a whole. Now, more than ever, the government of India is looking to U.S. companies for their expertise and high-end technology to provide solutions to some of India's most urgent problems.
About Implant Sciences (IMSC:$0.3500,$0.0000,0.00%)
Implant Sciences (IMSC:$0.3500,$0.0000,0.00%) develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Implant Sciences Corporation (IMSC:$0.3500,$0.0000,0.00%)
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Get more news on:SYMBOLS: IMSCNEWS TYPE: SECTORS:
Creditors take aim at $20 mln paid to WaMu's ex-CEO 09/14 10:25 AM
Sept 14 (Reuters) - Creditors of Washington Mutual Inc were cleared to try to recover payments the company made just before its bankruptcy, including $20 million paid to its last CEO, court papers show.
Judge Mary Walrath on Monday approved a deal between WaMu and its official unsecured creditor's committee which allows the creditors to take avoidance actions against more than 200 individuals and entities.
These names include Alan Fishman, WaMu's last chief executive, who held the position for 17 days before the company went bankrupt.
Reuters could not reach Fishman to comment on the development.
Fishman, who replaced Kerry Killinger on Sept. 8, 2008, was paid $20 million, including severance.
The thrift was closed by federal regulators and its banking assets sold to JPMorgan Chase & Co (JPM:$40.69,00$-0.43,00-1.05%) .
The case is In re Washington Mutual Inc (WAMUQ:$0.1810,$0.0010,0.56%) , U.S. Bankruptcy Court, District of Delaware (Wilmington), No. 08-12229. (Reporting by Santosh Nadgir in Bangalore; Editing by Maju Samuel)
Get more news on:SYMBOLS: JPM, WAMUQNEWS TYPE: SECTORS:
CEL-SCI Corporation Receives Approval from North Mississippi Health Services’ Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer 09/13 09:45 AM
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (CVM:$0.5097,$0.0097,1.94%) announced today it has received approval from the North Mississippi Health Services (“North Mississippiâ€) Institutional Review Board (“IRBâ€) to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.
CEL-SCI’s Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. North Mississippi is the first site in the United States to approve enrollment of subjects. CEL-SCI’s trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted. CEL-SCI (CVM:$0.5097,$0.0097,1.94%) plans to announce additional site approvals and country approvals as they become known.
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects’ tumors before the start of standard therapy. Follow-up studies of subjects enrolled in Phase II trials showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration gave clearance for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
About North Mississippi Health Services
North Mississippi Health Services (NMHS) is a diversified regional health care organization, which serves 24 counties in north Mississippi and northwest Alabama from headquarters in Tupelo, Mississippi. The NMHS organization covers a broad range of acute diagnostic and therapeutic services, offered through North Mississippi Medical Center in Tupelo; a community hospital system with locations in Eupora, Iuka, Pontotoc, West Point, Miss. and Hamilton, Alabama, North Mississippi Medical Clinics, a regional network of more than 30 primary and specialty clinics; and nursing homes. NMHS has an IRB that meets monthly. The NMHS IRB members include doctors, nurses, pharmacists, social workers, a lawyer, risk manager, and community members. This group reviews the science and ethics of the research. Their objective is to assess the risks and benefits to subjects involved in the study. The NMHS IRB has the authority to approve, require modification to, or disapprove all research activities that involve an NMHS investigator, facility, or patient group. Following initial approval, the IRB conducts periodic reviews of such research. In most instances, in order to approve research, an IRB must determine that specified criteria have been satisfied. Among these criteria, an IRB must determine that, when appropriate, the research protocol includes "adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data."
About CEL-SCI Corporation (CVM:$0.5097,$0.0097,1.94%)
CEL-SCI Corporation (CVM:$0.5097,$0.0097,1.94%) is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery. A pivotal Phase III clinical trial with Multikine in head and neck cancer is expected to start in the second half of 2010.
CEL-SCI (CVM:$0.5097,$0.0097,1.94%) is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI (CVM:$0.5097,$0.0097,1.94%) scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Source: CEL-SCI Corporation (CVM:$0.5097,$0.0097,1.94%)
Get more news on:SYMBOLS: CVMNEWS TYPE: SECTORS:
Implant Sciences Announces Over $550,000 in New Orders
Marks Continued Success in Growing Chinese and Spanish Safety and Security Markets 09/07 11:42 AM
WILMINGTON, MA -- (MARKET WIRE) -- 09/07/10 -- Implant Sciences Corporation (IMSC:$0.3100,$-0.0200,-6.06%) , a high technology supplier of systems and sensors for the homeland security and defense markets, today announced new orders totaling over $550,000 for its Quantum Sniffer? QS-H150 Portable Explosive Trace Detector.
These systems will be used in public safety and force protection applications in Spain and China. A study by IMS Research, one of the leading suppliers of detailed, quality market research to the global electronics industry, estimated the combined Chinese, Spanish, and Portuguese market for explosives, weapons and contraband detection at over $310 million in 2010.
Planned uses for the Quantum Sniffers bound for China include increasing public safety during the upcoming 2010 Asian Games, also called the XVI ASIAD. This year's event is the largest in the history of the games with a total of 476 events in 42 sports. In Spain, the QS-H150 will be deployed by the Spanish Air Force to enhance security.
"The Spanish Air Force order is the latest in a series from our in-country partner. Their continued success validates both the quality of our products and the strength of our distribution strategy," commented Bruce Bower, Senior Vice President of Implant Sciences (IMSC:$0.3100,$-0.0200,-6.06%) .
"These orders are new business in regions where Implant Sciences (IMSC:$0.3100,$-0.0200,-6.06%) has made previous sales. Our sustained success in these markets underscores the effectiveness and dependability of the QS-H150," stated Glenn Bolduc, CEO of Implant Sciences (IMSC:$0.3100,$-0.0200,-6.06%) .
About the Quantum Sniffer QS-H150
The QS-H150 Quantum Sniffer is a hand-held explosive trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.
About Implant Sciences (IMSC:$0.3100,$-0.0200,-6.06%)
Implant Sciences (IMSC:$0.3100,$-0.0200,-6.06%) develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Science's QS-H150 Portable Explosives Detector has been Designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the U.S. government or by other law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Implant Sciences Corporation (IMSC:$0.3100,$-0.0200,-6.06%)
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Get more news on:SYMBOLS: IMSCNEWS TYPE: SECTORS: Health Care, Electronic Equipment and Instruments, Information Technology, Electrical Equipment, Industrials
Bankruptcy Investigator Asks More Time On WaMu Pact Probe 09/07 11:08 AM
Court-appointed investigator Joshua Hochberg Tuesday asked a bankruptcy judge to give him until Nov. 1 to wrap up his probe of the proposed settlement of legal disputes arising out of the largest banking collapse in U.S. history--that of Washington Mutual Bank, or WaMu.
Hochberg has not yet reached conclusions about the settlement, which forms the underpinning of the proposed Chapter 11 plan of WaMu's former parent, Washington Mutual Inc. (WAMUQ:$0.2110,$-0.0020,-0.94%) , according to papers filed with the U.S. Bankruptcy Court in Wilmington, Del.
Hochberg, an attorney with McKenna Long & Aldridge and former Department of Justice fraud investigator, is expected to issue a report that will indicate whether Washington Mutual's (WAMUQ:$0.2110,$-0.0020,-0.94%) proposed settlement of a variety of legal actions is a fair deal for creditors owed an estimated $8 billion.
He is due to go before Judge Mary F. Walrath of the U.S. Bankruptcy Court in Wilmington, Del., Monday afternoon to talk about his preliminary report and seek an extension of time to complete it.
Filed with the court, the preliminary report outlines the ongoing investigation of the roots of WaMu's collapse, and the aftermath, including an agreement to split up tax refunds of $5.5 billion to $5.8 billion.
The proposed pact is with J.P. Morgan Chase & Co. (JPM), which bought WaMu after it was seized by regulators, and with the Federal Deposit Insurance Corp., which brokered the sale.
If Hochberg concludes the settlement is fair and the Chapter 11 plan is approved, Washington Mutual's (WAMUQ:$0.2110,$-0.0020,-0.94%) top-ranking creditors will have $7 billion to share, meaning windfall profits for those who bought the debt for pennies on the dollar soon after the loss of WaMu sent its former parent into Chapter 11 bankruptcy.
Shareholders and holders of trust-preferred securities issued by WaMu's former parent oppose the settlement, claiming it's designed to compensate top-ranking creditors while covering up serious flaws with the handling of the ailing thrift.
Stuffed with risky home loans, WaMu was taken over in September 2008 by regulators who feared it was on the brink of collapse and a threat to the stability of the U.S. financial system. Hearings before a Senate panel, however, have revealed that not all regulators believed WaMu was in such bad shape that it needed to be seized.
(Dow Jones Daily Bankruptcy Review covers news about distressed companies and those under bankruptcy protection.)
-By Peg Brickley, Dow Jones Daily Bankruptcy Review; 302-521-2266; peg.brickley@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=QVQAg5H3eeYRat0LgCv8jg%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
09-07-101108ET
Copyright (c) 2010 Dow Jones & Company, Inc.
Get more news on:SYMBOLS: JPM, WAMUQNEWS TYPE: Corporate Events: Mergers and Acquisitions, Corporate Events, Top Stories: General, Top Stories: Investing, Top NewsSECTORS: Commercial Banks, Thrifts and Mortgage Finance, Financials
Investigator Targets Nov 1 Release For Findings On WaMu Pact 09/07 11:10 AM
(MORE TO FOLLOW) Dow Jones Newswires
09-07-101110ET
Copyright (c) 2010 Dow Jones & Company, Inc.
Get more news on:SYMBOLS: JPM, WAMUQNEWS TYPE: Corporate EventsSECTORS: Commercial Banks, Thrifts and Mortgage Finance, Financials
Bankruptcy Investigator Asks More Time On WaMu Pact Probe 09/07 11:08 AM
(MORE TO FOLLOW) Dow Jones Newswires
09-07-101108ET
Copyright (c) 2010 Dow Jones & Company, Inc.
Get more news on:SYMBOLS: JPM, WAMUQNEWS TYPE: Corporate EventsSECTORS: Commercial Banks, Thrifts and Mortgage Finance, Financials
Genta Incorporated to Present at the Rodman & Renshaw Annual Global Investment Conference [webcast] 09/07 08:05 AM
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)-- announced that the Company’s Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 13th at 4:05 pm EDT. The conference will be held at The New York Palace Hotel in New York City.
The presentation will be webcast and accessible at the Investor Relations section of the Company’s website at http://www.genta.com/investorrelation/events.html. The presentation will be archived for 30 days.
About
Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has completed or is continuing evaluation in a broad program of Phase 2a and Phase 2b clinical trials. The Company has announced that gastric (stomach) cancer will be the lead indication for Phase 3 registration studies. Genasense® (oblimersen sodium) Injection is a modified DNA-based antisense drug that may enhance the effectiveness of anticancer therapy. has completed enrollment in a randomized, double-blind Phase 3 study of Genasense® in patients with advanced melanoma, known as “AGENDAâ€. Final data on survival and durable response from AGENDA, which may be pivotal for regulatory approval, are expected in the first half of 2011. is exclusively marketing Ganite® (gallium nitrate injection) in the U.S, which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite® that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite® and Genasense® are available on a “named-patient†basis in countries outside the United States. For more information about , please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact.The words “potentiallyâ€, “anticipateâ€, “couldâ€, “calls forâ€, and similar expressions also identify forward-looking statements.The Company does not undertake to update any forward-looking statements.Factors that could affect actual results include, without limitation, risks associated with:
the Company’s ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
the safety and efficacy of the Company’s products or product candidates;
the commencement and completion of any clinical trials;
the Company’s assessment of its clinical trials;
the Company’s ability to develop, manufacture, license, or sell its products or product candidates;
the Company’s ability to enter into and successfully execute any license and collaborative agreements;
the adequacy of the Company’s capital resources and cash flow projections, or the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks to the Company’s Business as described in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially.For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2009 and its most recent quarterly report on Form 10-Q.
Source:
Get more news on:SYMBOLS: NEWS TYPE: SECTORS: Pharmaceuticals, Health Care
KAT Exploration Inc. to Drill Test IOCG Targets at Rusty Ridge 09/01 09:50 AM
MOUNT PEARL, NL -- (MARKET WIRE) -- 09/01/10 -- KAT Exploration, Inc. (KATX:$0.0900,$0.0000,0.00%) (www.katexploration.com) is pleased to inform its shareholders and investment community that the company is now ready to begin drilling on its 100% wholly owned Rusty Ridge Iron Oxide Copper Gold (IOCG) property. Tenders are being called for the drilling program, and as announced earlier, all permits are in place with two distinct targets being defined for deep drilling.
Results of a high resolution airborne magnetic survey, a ground gravity survey along with coincidental magnetic Induced Polarization (IP) resistivity and soil geochemical anomalies suggest potential for a body of Iron Oxide +/- Base, Precious and Rare Earth type mineralization, similar in style and setting to the giant Olympic Dam deposit in Australia.
A completed 3D inversion modeling of the airborne magnetic data shows a discreet, strong magnetic anomaly underlying the Rusty Ridge area. Coincidental with this are moderate to strong IP chargeability anomalies that suggest the possibility of a significant concentration of sulfides. A 3D inversion model of the ground gravity survey identified a large gravity anomaly and several other smaller anomalies further supporting the potential for an IOCG deposit. Selected coincident gravity, magnetic and IP anomalies, including the large gravity anomaly, will now be drill tested to determine the significance of these targets.
Ken Stead, President/CEO of KAT Exploration (KATX:$0.0900,$0.0000,0.00%) , stated, "That although the targets to be drilled are deep targets, what is most exciting and of interest is that the anomalies are also 400-500 meters thick. If these targets prove to be thick mineralized units similar to that of the Olympic dam, it will be the first for the province and will no doubt generate a tremendous positive impact for the company."
This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Kat Exploration Inc. (KATX:$0.0900,$0.0000,0.00%) to be materially different from the statements made herein.
Jack ZwickerKat Exploration Inc (KATX:$0.0900,$0.0000,0.00%)
Investor Relations
Ph 902-497-3188
jzwicker@katexploration.com
www.katexploration.com
Get more news on:SYMBOLS: KATXNEWS TYPE: SECTORS:
Far from a completely "done deal"
"........The plan will become effective and Visteon will emerge from Chapter 11 upon completion of necessary closing conditions, which Visteon expects to occur by Oct. 1. ......."
A lot can happen from now to October 1....
http://www.prnewswire.com/news-releases/court-confirms-visteons-plan-of-reorganization-101893838.html
Orphaned' Shareholders Call Visteon Restructuring Plan Unfair
Peg Brickley | 30 August 2010
Visteon Corp. faces a last-ditch effort by "orphaned" shareholders who say its Chapter 11 restructuring plan means unequal treatment for equity stakeholders, with the advantage going to those who banded together in an informal committee.
Car parts-maker Visteon is due to go before a bankruptcy judge Tuesday to seek confirmation of its Chapter 11 plan, having made peace with banks, bondholders and with some shareholders.
The deal Visteon cut with shareholders who formed an ad hoc committee is under attack from rank-and-file shareholders, who say they're being deprived of an equal chance to participate in Visteon's revival. Neither the ad hoc committee nor Visteon's management was interested in looking out for shareholders in general, they say.
"In effect, we are orphaned," wrote Diana Diebler of North Tonawanda, N.Y., in a letter last week to the bankruptcy court.
Daily Bankruptcy Review
'Orphaned' Shareholders Call Visteon Restructuring Plan Unfair
Peg Brickley | 30 August 2010
Federal bankruptcy watchdogs are backing the unhappy shareholders, saying it's not right for the company to give better treatment to members of the ad hoc committee than it is giving to its existing equity stakeholders.
Visteon is giving all shareholders a chance to share 2% of the equity in the revived operation. Members of the ad hoc committee also get up to $4.25 million of their legal fees paid, and enhanced investment rights.
"This disparate treatment has not been lost on the shareholders who do not sit on the" ad hoc equity committee, wrote U.S. Trustee Roberta A. DeAngelis in a filing Friday with the U.S. Bankruptcy Court in Wilmington, Del.
DeAngelis, an officer of the Department of Justice, said it's particularly unfair because Visteon didn't reveal the special ad hoc committee arrangement until after ballots had been cast on its Chapter 11 plan.
Visteon says it has votes of support from all classes of creditors for its reorganization plan, the culmination of a 15-month stay in bankruptcy that began with the automotive industry in crisis. Bondholders including Stark Investments, UBS Securities, Citadel Securities, Goldman Sachs Group Inc. and Silver Point Capital will take over the company if the Chapter 11 plan is confirmed.
Martin Bienenstock of Dewey & LeBoeuf, attorney for the ad hoc committee, could not immediately be reached Monday to comment on the complaints from rank-and-file shareholders.
Visteon's lead bank lenders, however, said in a court filing that the ad hoc committee members took the risk that their intensive battles with the company would not pay off, and hence deserve a greater reward.
The shareholder fight in Visteon highlights the growing role informal committees play in corporate reorganizations. Hedge fund investors prefer the anonymity and trading freedom that comes with membership on an ad hoc committee, as compared with a formal Chapter 11 committee. Instead of having to look out for all creditors in their class, members of informal committees say they have only their own self-interest to protect.
In Visteon's case, there was a drive for a formal shareholder committee, but it failed. Visteon shareholders say the preferred treatment members of the ad hoc committee are receiving under the company's Chapter 11 plan is the natural product of the court's refusal to appoint a formal committee.
In letters to the bankruptcy court, "orphaned" Visteon shareholders say the company is low-balling them in an effort to strip equity stakeholders of as much value as possible. A debate over how much Visteon is actually worth as a survivor of the shake-out in the automotive sector raged for months, until the company reached settlements with most major creditor constituencies.
Wilmington Trust, as agent for bank lenders, said in a court filing Sunday that it's too late for anyone to raise valuation arguments, because the expert witnesses who would be called on for evidence have never been put to work. Tuesday should be the day Visteon gets court approval to exit bankruptcy, the banks said.
"There is occasion neither for further delay nor further hearings," Wilmington Trust attorneys wrote.
Document DJFDBR0020100830e68u0005m
(c) 2010 Dow Jones & Company, Inc.
https://www.fis.dowjones.com/WebBlogs.aspx?aid=DJFDBR0020100830e68u0005m&ProductIDFromApplication=&r=wsjblog&s=djfdbr
Visteon forms JV with Russian company
Visteon forms joint venture with Russian company to provide vehicle electronics
On Thursday August 26, 2010, 4:29 pm EDT
VLADIMIR, Russia (AP) -- Auto parts supplier Visteon Corp. said Thursday that it has formed a joint venture with a Russian company, Avtopribor, to provide vehicle cockpit electronics to the Russian auto market.
The venture, called OOO Visteon Avtopribor Electronics, will make products such as audio equipment, infotainment devices and driver information and control electronics.
It will be based in Vladimir, located to the east of Moscow. Visteon said it will supply Russian automakers such as AvtoVAZ, Russian's largest car manufacturer, as well as Ford Motor Co.
Visteon seeks court OK for $700 mln exit financing 08/26 07:17 AM
* Morgan Stanley lead arranger for financing
* Visteon (VSTNQ:$0.5355,$0.0305,6.04%) wants to emerge from bankruptcy this fall
* Hyundai, Ford are its biggest customers (Adds details on exit financing, background on the bankruptcy case)
DETROIT, Aug 26 (Reuters) - U.S. auto parts supplier Visteon Corp (VSTNQ:$0.5355,$0.0305,6.04%) has asked a federal bankruptcy court to approve $700 million in financing so it can exit its 15-month bankruptcy, court documents filed on Wednesday show.
A hearing before the U.S. Bankruptcy Court in Delaware is to be held next Tuesday to confirm the plan.
Visteon (VSTNQ:$0.5355,$0.0305,6.04%) plans to emerge from bankruptcy in late September or early October based on a confirmation of the plan on Tuesday and meeting other requirements, Visteon (VSTNQ:$0.5355,$0.0305,6.04%) spokeswoman Julie Fream said.
Morgan Stanley was selected as lead arranger for the exit financing, which includes a $500 million senior secured term loan and $200 million of senior secured asset-based revolving credit, according to papers filed with the court.
Reuters first reported the exit financing details earlier in August based on sources with knowledge of the matter.
Visteon (VSTNQ:$0.5355,$0.0305,6.04%) , the former parts unit that Ford Motor Co (F:$11.37,00$0.0500,0.44%) spun off in 2000, filed for court protection in May 2009 as the economic downturn pushed auto sales to the lowest levels in three decades and automakers General Motors and Chrysler fell into government-supported bankruptcies.
The company restructured operations and cleaned its balance sheet in bankruptcy. Visteon (VSTNQ:$0.5355,$0.0305,6.04%) sales rose 32 percent to $3.85 billion in the first half of 2010 from the first half of 2009 and it posted a $32 million net profit.
Visteon (VSTNQ:$0.5355,$0.0305,6.04%) , which produces electronics, lighting and interior components for autos, rejected an unsolicited $1.25 billion cash bid from Johnson Controls Inc (JCI:$27.014999,$0.135000,0.50%) for most of the company's assets three months ago.
Ford and Hyundai Motor Co (HYMLF:$66.6000,$0.0000,0.00%) are Visteon's (VSTNQ:$0.5355,$0.0305,6.04%) biggest customers, comprising nearly 30 percent each of its sales, Fream said.
Visteon (VSTNQ:$0.5355,$0.0305,6.04%) said the subscription period for its rights offering ended on July 30, and that its eligible unsecured noteholders delivered checks for more than $1.06 billion into escrow.
The amount exceeds the $950 million equity rights offering upon which Visteon's (VSTNQ:$0.5355,$0.0305,6.04%) primary reorganization plan is premised, the filing said on Wednesday.
The case is Visteon Corp (VSTNQ:$0.5355,$0.0305,6.04%) , U.S. Bankruptcy Court, District of Delaware, No. 09-11786. (Reporting by Bernie Woodall in Detroit and Santosh Nadgir in Bangalore; Editing by Gopakumar Warrier and Robert MacMillan)
Get more news on:SYMBOLS: VSTNQ, F, JCI, HYMLFNEWS TYPE: Market Headlines, Top Stories: General, Top News, Bonds, Corporate Events: Mergers and Acquisitions, Corporate Events, Personal FinanceSECTORS: Automobiles, Auto Components, Consumer Discretionary
Implant Sciences Invited to Participate in Executive Trade Mission to India
Implant Executives to Meet With Key Decision Makers at Each of India's Security Agencies; Building Upon Prior Sales to India 08/26 10:57 AM
WILMINGTON, MA -- (MARKET WIRE) -- 08/26/10 -- Implant Sciences Corporation (IMSC:$0.2800,$-0.0400,-12.50%) , a high technology supplier of systems and sensors for homeland security markets, today announced that it has been selected to join an executive trade mission to India beginning on September 6, 2010. Implant Sciences (IMSC:$0.2800,$-0.0400,-12.50%) was one of a select few companies invited to participate, based on the Company's success in deploying its Quantum Sniffer ? QS-H150 handheld explosive trace detectors in defense and law enforcement agencies throughout India.
The U.S.-India Business Council (USIBC), formed in 1975 at the request of the Government of India and the U.S. Government to advance commercial ties between the world's two largest free-market democracies and hosted under the aegis of the U.S. Chamber of Commerce in Washington, DC, is leading the trade mission in advance of President Obama's highly anticipated November visit to India. USIBC has previously led nine aerospace & defense executive missions to India since 2001 promoting a deeper defense and strategic partnership between both countries. During the mission, Implant Sciences (IMSC:$0.2800,$-0.0400,-12.50%) expects to be introduced to leaders of India's homeland security and defense agencies, including the National Security Advisor, Foreign Secretary, Director General of the Indian Coast Guard, Director General of the Central Reserve Police Force, and others.
In the aftermath of the November 2008 attacks in Mumbai, the Government of India has embarked on an ambitious plan to modernize and upgrade its homeland security apparatus. The homeland security budget has been growing at an annual rate of 25% to fund the planned improvements in police and paramilitary forces, secure urban centers against terrorism and create a safe economic environment for the country as a whole. Now, more than ever, the Government of India is looking to U.S. companies for their expertise and high-end technology to provide solutions to some of India's most urgent problems.
Glenn Bolduc, CEO of Implant Sciences (IMSC:$0.2800,$-0.0400,-12.50%) , commented, "We are extremely pleased to have been invited by the USIBC to participate in this important trade mission. India is the world's largest democracy and an important ally to the United States and Implant Sciences (IMSC:$0.2800,$-0.0400,-12.50%) is proud of its contribution towards enhancing the security of India and its citizens. We look forward to the opportunity to build on our success in the country."
About Implant Sciences (IMSC:$0.2800,$-0.0400,-12.50%)
Implant Sciences (IMSC:$0.2800,$-0.0400,-12.50%) develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Implant Sciences Corporation (IMSC:$0.2800,$-0.0400,-12.50%)
Company Contact:
Glenn Bolduc, CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
Get more news on:SYMBOLS: IMSCNEWS TYPE: SECTORS: Electronic Equipment and Instruments, Information Technology, Aerospace and Defense, Electrical Equipment, Industrials
VSTNQ - Getting ready for an EXPLOSION ?
Hopefully upwards .......
CHART
http://stockcharts.com/h-sc/ui?s=VSTNQ&p=D&yr=0&mn=6&dy=0&id=p52388504784
More Detail YRC Worldwide - Request More Time To Enact Reverse Split 08/25 10:30 AM
YRC Worldwide Inc. (YRCW:$0.2623,$0.0053,2.06%) is holding out the possibility that it may seek an extension to an Aug. 30 deadline to enact a reverse stock split and boost its share price above $1 or face Nasdaq delisting.
Executives of the struggling trucking company, which last traded above $1 a share on Jan. 15, said through a spokeswoman Wednesday that they remain intent on avoiding delisting by enacting a reverse split.
But they also said the precise date of the move "will take into account the timing of any appeals," meaning it might not happen by the Monday deadline if YRC seeks an extension.
YRC shares were trading recently around 26 cents. YRC previously has said the planned reverse split will range from 1:25 to 1:5.
The company declined to reveal a reason for what have been repeated delays. Beginning in March, it reiterated several times that it expected to enact the reverse split during the second quarter, but in June it noted that it technically had until Aug. 30 to satisfy the Nasdaq stock market listing requirements.
Chief Financial Officer Sheila Taylor said during the company's second-quarter earnings conference call earlier this month that YRC has "every intention of working with Nasdaq to stay in compliance with listing requirements," although she said the board hadn't finalized the timing of the reverse split.
YRC's spokeswoman said Wednesday the board "will consider what they're going to do in the next couple of weeks," taking into account the possibility of an appeal.
Regardless, Robert W. Baird & Co. analyst Jon Langenfeld said he doesn't consider delisting to be a serious concern for YRC investors. He has an underperform rating on the stock for other reasons.
"My thought is they will not be delisted," Langenfeld said. "If it comes down to them not getting the extension, they would just go ahead and have the reverse split. The board has the authorization [from shareholders] to do that."
-By Bob Sechler, Dow Jones Newswires; 512-258-1690; bob.sechler@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=PL8KSeuz4HY0IaGSxX%2F4DA%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
08-25-101030ET
Copyright (c) 2010 Dow Jones & Company, Inc.
Get more news on:SYMBOLS: YRCWNEWS TYPE: SECTORS: Road and Rail, Industrials
Yes I am ... (although I am Underwater at present)
EEE seems to be doing well today.
A lot of institutions (Including Vanguard, Blackrock etc.) own it at present.
It shows here, if this is relatively current:
http://finance.yahoo.com/q/mh?s=EEE+Major+Holders
MedeFile Updates Shareholders 08/24 08:52 AM
BOCA RATON, Fla., Aug. 24 /PRNewswire-FirstCall/ --  Kevin Hauser, Chief Executive Officer of  MedeFile International, Inc. (MDFI:$0.0055,$-0.0004,-6.78%) , issues the following update to the shareholders of MedeFile International, Inc. (MDFI:$0.0055,$-0.0004,-6.78%) :
To the shareholders of MedeFile International, Inc. (MDFI:$0.0055,$-0.0004,-6.78%) ,
I am pleased to report that MedeFile International, Inc. (MDFI:$0.0055,$-0.0004,-6.78%) is in an optimal strategic position. Â Even in today's uncertain economic climate, MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) has maintained our position at the forefront of the health information technology revolution. Â With the use of electronic medical records set to grow substantially by 2014 under the HITECH Act of 2009, MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) is ready to dominate a quickly expanding market in Personal Health Records Management.
The company continues to be a major player in the exploding field of Personal Health Records, and is poised for continued, long-term growth, uniquely positioned at the convergence point of healthcare and technology; two areas which we believe will be the fastest growing areas of the global economy in the 21st Century.
In recent months, our efforts have resulted in numerous opportunities for continued growth and success:
* We've secured new, mass-market distribution agreements, while also targeting niche markets and customizing products for those markets.
Always on the lookout for avenues to new, mass market opportunities (as well as some smaller, strategic ones) we have recently signed several pivotal distribution agreements that will provide immediate growth as well as ongoing opportunities to enhance our reach. Â Some of these agreements include National Safe Drivers (NSD), one of the country's largest suppliers of auto-related supplemental products, giving us direct access to their massive pool of auto-related customers (5 million+ individuals) and our joint venture agreement with The More Network (TMN), a premier provider of business-to-business solutions, products and services to the robust transportation industry.
* We are vertically marketing through private physician practices and have created our first-ever direct-to-consumer marketing campaign that has just recently launched.
We recently rolled out a revolutionary program targeted to physicians, which enables practices to seamlessly incorporate MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) 's PHR technology into their existing workflow. Â This program also allows electronic interfacing with EMR technology as well as paper based offices to market the MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) system as well. Â We expect this marketing campaign to result in a substantial flow of new MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) memberships from within each participating practice's patient base. We will continue to pursue vertical marketing through private physicians' offices, thus increasing our local and national footprint and improving consumer affinity for our brand through the explicit endorsement and direct recommendation of trusted health care providers.
* We continue to strengthen our cumulative experience, knowledge and influence with strategic, high-profile additions to our Board of Advisors.
We have recently welcomed Howard Mofshin to our Board of Advisors. Â He is the ground-breaking direct response marketing expert and successful venture capitalist who co-founded "Cash4Gold," one of the fastest growing companies in America. Â Mr. Mofshin, who ideated and instituted perhaps the most successful direct response commercial in television advertising history, brings his substantial experience and expertise in direct response marketing to MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) , with the goal of further developing and effectively executing our long-term marketing agenda.
* We have evolved the MedeFile brand and upgraded our website to reflect the corresponding growth in the company and new developments in technology, healthcare and in the field of PHR Technology.
The redesigned MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) website - clearer, more sophisticated, and more informative than ever - was recently launched to an overwhelmingly positive response. Â In concert with the redesign of our online presence, we've fine-tuned our Mission Statement: Â
To provide our members and the healthcare community with 21st Century solutions for navigating the increasingly complex and ever-changing healthcare and medical environment.
* Direct marketing is a key pillar of our overall growth strategy. After a comprehensive process of research and refinement, we are deploying an ambitious direct-to-consumer marketing campaign. This new campaign will enable even more reach and specificity in terms of the demographics we target. Â We anticipate this will result in more customers and increased growth of our subscriber base. Â MedeFile is now geared up to market to consumers directly through intensive direct response marketing and through various media such as TV, web video, social networks, and telemarketing. Â Early returns from these various campaigns are extremely promising.
In addition to all these efforts, we recently made huge strides in the expansion of our resources through significant new capital investment as well as via the recent strengthening of our balance sheet to make MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) totally free of debt, providing the company with substantial working capital for aggressive marketing campaigns. Â We are pleased to report that the new capital we have attracted was injected by long-term investors who share the vision of our management team. Â Additionally, our single largest shareholder has increased his equity position in MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) . Â Other shareholders should be comforted to know that our single largest shareholder is committed to the long term goals and success of MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) . Â This additional capital will support the anticipated growth in sales and marketing, scanning operations, fulfillment operations and call center operations that are mission critical for our overall expansion.
All of this capital - financial and otherwise - allows us to continue to develop newer and better solutions and to exploit growth opportunities, wherever and whenever they arise.
The ongoing efforts and developments described above have landed MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) at the center of the medical information technology revolution. This successful positioning has been made possible by the progressive and entrepreneurial vision of our management, the diligent and comprehensive work of our employees, and our strategic positioning and efficient use of capital.
On behalf of the entire MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) team, I hope that this update provides a clear picture of our many recent activities and developments, as well as an appreciation for the many successful outcomes we have achieved and expect to achieve on behalf of our shareholders.
Before I conclude, I want to add that I was honored this month to assume the position of Chief Executive Officer of MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) . Â As I take the helm from my capable predecessor (my father, Milton Hauser), I am proud to be leading this wonderful company during what I expect to be the most exciting time in its history. Â
I am strongly committed to increasing shareholder value and will do everything in my power serve your interests as a shareholder in MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) , and to communicate clearly with you as we continue to execute on our business plan. Â Thank you for the opportunity to provide this update on your investment in the future of healthcare information technology. Â
Sincerely yours,
Kevin Hauser
Chief Executive Officer, MedeFile (MDFI:$0.0055,$-0.0004,-6.78%)
About MedeFile International, Inc. (MDFI:$0.0055,$-0.0004,-6.78%)
Headquartered in South Florida, MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) has a proprietary system for gathering and digitizing medical records so that individuals can have a comprehensive record of all of their medical visits. MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) 's primary product is the MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) system, a highly secure system for gathering and maintaining medical records. The MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) system is designed to gather all of its members' actual medical records and create a single, comprehensive medical record that is accessible 24 hours a day, seven days a week. For more information about MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) and its annual subscription-based programs, please visit www.medefile.com
Safe Harbor Statement Under the Private Securities Litigation Act of 1995
With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of MedeFile (MDFI:$0.0055,$-0.0004,-6.78%) could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the Company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates, and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, and such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, review our SEC filings.
Contact: Â Investors, MedeFile International, Inc. (MDFI:$0.0055,$-0.0004,-6.78%) , 1-888-241-0800, Â investor@medefile.com
SOURCE MedeFile International, Inc. (MDFI:$0.0055,$-0.0004,-6.78%)
Get more news on:SYMBOLS: MDFINEWS TYPE: SECTORS: Health Care Providers and Services, Health Care, Communications Equipment, Computers and Peripherals, Internet Software and Services, IT Services, Software, Information Technology, Electrical Equipment, Industrials
Form 8-K EVERGREEN ENERGY INC For: Aug 20 08/24 08:01 AM
xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7120230
Filed on: August 24, 2010
Evergreen Energy Signs Definitive Agreement to Sell its Landrica
Development Company Assets Including the Fort Union Plant
- Sale to provide approximately $8.3 million -
DENVER, August 24, 2010 — Evergreen Energy Inc. (NYSE Arca: EEE) today announced that it has signed a definitive agreement with Synthetic Fuels LLC for the sale of the assets of its Landrica Development Company, including the Fort Union plant and associated property located near Gillette, WY.
The sale will provide approximately $8.3 million of available cash to the Company, comprised of: (i) cash payments of $2.0 million, payable $500,000 at closing, an additional $500,000 on the first anniversary of closing and $1.0 million on the second anniversary of closing; and (ii) the release of approximately $6.3 million of reclamation bonds upon the replacement of such bonds by Synthetic Fuels. The obligation to replace the reclamation bonds is evidenced by a secured promissory note in the amount of $6.3 million payable 12 months following the closing. The sale is anticipated to close in the fourth quarter of 2010 and is subject to customary closing conditions. Proceeds of the sale will be used for general working capital purposes.
“The sale of Landrica and the Fort Union plant represents the achievement of another significant milestone as Evergreen completes the goal to shed non-core assets and evolve into a pure clean technology company,” stated Thomas H. Stoner, CEO and director of Evergreen. “This transaction and the recent sale of Buckeye will allow our team to further focus on building revenue and net income via our two clean technologies – GreenCert™ and K-Fuel® – thereby delivering value to our shareholders.”
Evergreen Energy’s Fort Union facility is a 1,200 acre non-producing coal mine located northwest of Gillette, WY. Site activities at Fort Union have been limited primarily to laboratory testing and site maintenance activities required for safety and environmental management purposes since 2008. In conjunction with the sale, a separate agreement will be negotiated with the Buyer, which will allow Evergreen to continue to perform feedstock validation testing in its existing laboratory at the site.
Evergreen Energy Inc.
Evergreen Energy Inc. (NYSE Arca: EEE) has developed two proven, proprietary, patented, and transformative green technologies: the GreenCert™ suite of software and services and K-Fuel®. GreenCert, which is owned exclusively by Evergreen, is a scientifically accurate, scalable environment intelligence solution that measures greenhouse gases and generates verifiable emissions credits. K-Fuel technology significantly improves the performance of low-rank coals yielding higher efficiency and lowering emissions. Visit www.evgenergy.com for more information.
Synthetic Fuels LLC
Synthetic Fuels LLC is a Colorado company formed by energy executive James Nairne of Dallas. Synthetic Fuels has rights to proprietary coal gasification/liquefaction technology, with plans to utilize this technology in the construction and operation of a commercial coal-to-liquids facility on the Ft. Union site.
Nairne and his team of professionals have over fifty years of experience in energy project development, including conventional electrical generation from hydrocarbons as well as from renewable sources. "America is not short of energy sources." Nairne said. "What we lack are liquid transportation fuels from domestic resources. Using our vast coal reserves as feedstock for diesel and jet fuels, our mission is to give our contribution to American energy security."
Safe Harbor Statement
Statements in this release that relate to future plans or projected results of Evergreen Energy Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended by the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), and Section 21E of the Securities Exchange Act of 1934, as amended by the PSLRA, and all such statements fall under the "safe harbor" provisions of the PSLRA. Our actual results may vary materially from those described in any "forward-looking statement" due to, among other possible reasons, the realization of any one or more of the risk factors described in our annual or quarterly reports, or in any of our other filings with the Securities and Exchange Commission, all of which filings any reader of this release is encouraged to study. In addition, our ability to execute our business plan and develop the GreenCert™ or K-Fuel® technologies may be adversely impacted by an unfavorable decisions in the Buckeye litigation, which will limit our ability to utilize the proceeds received from the sale of Buckeye, completion of the sale of Ft. Union and the release of the bond funds, and our ability to raise significant additional capital or effectively complete any restructure transaction on a timely basis to fund our business operations. Readers of this release are cautioned not to put undue reliance on forward-looking statements.
Evergreen Investor Contact:
Kirsten Chapman & Becky Herrick
Lippert / Heilshorn & Associates
415.433.3777
bherrick@lhai.com
Not sure if it "owns" or recently "bought" ?
GOLDMAN SACHS GROUP INC owns 5,079,455 Shares Common Stock
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
"FORM 3"
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Name and Address of Reporting Person*GOLDMAN SACHS GROUP INC
200 WEST STREET NEW YORKNY10282
Common Stock 5,079,455 Shares
Date of Event Requiring Statement (Month/Day/Year)
08/09/2010
http://phx.corporate-ir.net/phoenix.zhtml?c=122447&p=irol-SECText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDExNDAzNjEtMTAtMDM0MzcyL3htbA%3d%3d
A 60% Premium for MFE ...not enough?
Ryan & Maniskas, LLP Announces Investigation of McAfee, Inc. 08/19 12:15 PM
WAYNE, Pa.--(BUSINESS WIRE)-- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/mfe) is investigating potential claims against the board of directors of McAfee, Inc. (MFE:$47.10,00$17.1700,57.37%) ("McAfee" or the "Company") concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Intel Corp.
(INTC:$18.96,00$-0.63,00-3.22%) in a transaction with a value of approximately $7.68 billion.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of McAfee (MFE:$47.10,00$17.1700,57.37%) . For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/mfe.
Under the terms of the proposed transactions, McAfee (MFE:$47.10,00$17.1700,57.37%) shareholders will receive $48.00 cash for each share of McAfee (MFE:$47.10,00$17.1700,57.37%) common stock they own.
If you own shares of McAfee (MFE:$47.10,00$17.1700,57.37%) and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/mfe. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan and Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
Source: Ryan & Maniskas, LLP
Get more news on:SYMBOLS: MFE, INTCNEWS TYPE: SECTORS: Computers and Peripherals, Internet Software and Services, IT Services, Software, Information Technology, Commercial Services and Supplies, Industrials
So do I ... Hate McAfee
I cant understand WHY Intel paid this huge 60% premium for McAffee.
($7.68 billion, or $48 per share.)
The market does not like it ...
Punishing the stock....Down almost 3%
BIEL: Time For An Upswing? ....(Article is 2 days old)
By: Vinny Cassano Monday, August 16, 2010 1:19 PM
It's been a little while since I last commented on BioElectronics Corp, but BIEL is definitely still a stock that I've got my eye on, and I expect a huge rebound in price if expected developments finally materialize for the company.
The biggest news that investors are waiting for is news that the FDA has granted over-the-counter (OTC) clearance for the company's products in the United States. Investors are also looking for sales numbers, since the ActiPatch and Allay products are already on sale in various markets around the globe, in addition to the ActiPatch being available to US consumers through Amazon.com.
However, as investors sit and wait for news and updates, the BIEL share price has continued its downward spiral towards a penny. While frightening for many investors who are averaged in at significantly higher prices, I'm still taking advantage of this price decline and I've nearly doubled my position over the past few trading sessions, with my lowest buy order being filled at .0105 earlier in the week.
Developments may be slow in coming, but I'm highly confident in the future of BioElectronics, barring any definitive negative action by the FDA regarding the broad approval of the submitted 501k applications. That said, it's important to note that the company needs decent international growth to stay afloat during the long wait, and dilution becomes a concern if the company needs to raise significant funds before sales numbers increase enough to offset costs.
One development on the product front that, curiously, has not been mentioned by BioElectronics is that the ActiPatch and Allay products have received a Class II designation in Japan. YesDTC, BIEL's exclusive distributor in Japan, has already issued a press release on this news, but BioElectronics has - to date - has had nothing to say.
Regardless, the news is good for BIEL no matter how you look at it.
Although nothing has hit the wires in the form of a press release of late, aside from updates on the DRTV campaigns in England and Canada a couple of weeks ago, President Andrew Whelan has posted a letter to shareholders on the company's web site.
In that letter, the President speaks very confidently about the company's future and states that BioElectronics is "certain" that "FDA clearance is inevitable and close."
I'm wary when the President of a company speaking in such definitive terms, because nothing is certain in the medical device and biotech market, and if an outcome was so certain, I believe that we would have seen a news release as such. In my opinion, these words are either an act of desperation by Mr. Whelan as the share price of his company tanks or he knows something that he probably shouldn't indicate to us that he knows.
As always there are concerns with an investment in BIEL, but patient investors who still believe that the BioElectronics products have huge potential as alternatives to the associated health risks of Tylenol and Ibuprofen should be taking advantage of these share prices. I looked at anything below three cents as my "load up" price, and I'm loving the near-penny opportunity to buy. The drop has taken the better part of a year to take place, but a recovery can be instant - that's the nature of the game, and I plan on being fully vested if/when a recovery takes place.
On that note, however, I've also got a handful of trading shares that I'll play with on the less significant spikes and dips, because as we all know - nothing is "certain" in this market and we've got to protect our investments as we see fit.
On another note, stock promoter Joe Noel has discontinued coverage of the BIEL stock on his website, although he is still heavily connected to BioElectronics as the CEO of YesDTC.
The wait continues, but I'm still a big fan of the potential returns that can be realized from this stock; and I'm still buying.
Each investor should do his or her own DD and invest accordingly.
Disclosure: Long BIEL.
http://www.istockanalyst.com/article/viewarticle/articleid/4411256
Chart shaping nicely ...FWIW
http://stockcharts.com/h-sc/ui?s=BIEL&p=D&yr=0&mn=6&dy=0&id=p92354980175
The Hail Mary Plan to Get J.P. Morgan to Pay More for WaMu
* August 18, 2010, 2:51 PM ET
During the depths of the financial crisis in 2008, J.P. Morgan Chase snapped up the banking assets of failed Seattle thrift Washington Mutual for a bargain $1.88 billion.
Now one Washington Mutual shareholder says he has discovered a way the New York bank could pay more if regulators were to ask.
Bloomberg News
http://blogs.wsj.com/deals/2010/08/18/the-hail-mary-plan-to-get-jp-morgan-to-pay-more-for-wamu/
The Federal Deposit Insurance Corp. and J.P. Morgan, as it turns out, never completed a “final settlement” of the sale, even though the $1.88 billion was delivered to the FDIC after Washington Mutual’s Sept. 25, 2008, seizure. Legally, this means the deal isn’t yet done.
The most recent extension of a final settlement expires Aug. 30, 2010, according to a document obtained by shareholder Farokh Karani Lam via a Freedom of Information request. The original purchase and assumption agreement gave FDIC the right to extend the settlement “in its discretion.” The document obtained by Lam is an amendment to that original agreement.
Lam, among the shareholders who saw their shares plunge into the low singe digits in the months before the seizure and had their remaining holdings virtually wiped out, said Washington Mutual’s assets could be revalued upward and FDIC could go back to J.P. Morgan to ask for a higher price. The FDIC, he said, kept the settlement option open “to protect themselves.” Lam said his Washington Mutual shares now trade in the pennies.
But an FDIC spokesman said extensions of purchase settlements are “quite common” and “have been the rule rather than the exception” on bank seizures and sales since 2007. Such extensions, he said, are often needed as regulators and the acquiring institution work out “administrative issues” such as options on leases, contracts or branch offices. The spokesman declined comment on the possibility of going back to J.P Morgan for a higher price.
J.P. Morgan declined comment.
A lawyer representing bank bondholders said she doesn’t expect the settlement extension to result in a request for a higher price for Washington Mutual’s banking assets, as much as her clients might want that to happen. Bondholders have been fighting with the FDIC, J.P. Morgan and Washington Mutual’s bankrupt parent company over the remaining assets that belonged to the parent when the thrift was seized. A potential settlement of those claims has not yet been approved by the court.
Washington Mutual was “sold too cheap,” said Renee Dailey, a partner with Bracewell & Giuliani LLP. But “I’m not sure an extension of the settlement date means FDIC is going after a larger purchase price. I don’t think they are planning to do that at all.”
“Our clients,” she added, “think that is unfortunate.”
Copyright 2008 Dow Jones & Company, Inc. All Rights Reserved
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit
The Hail Mary Plan to Get J.P. Morgan to Pay More for WaMu
* August 18, 2010, 2:51 PM ET
During the depths of the financial crisis in 2008, J.P. Morgan Chase snapped up the banking assets of failed Seattle thrift Washington Mutual for a bargain $1.88 billion.
Now one Washington Mutual shareholder says he has discovered a way the New York bank could pay more if regulators were to ask.
Bloomberg News
The Federal Deposit Insurance Corp. and J.P. Morgan, as it turns out, never completed a “final settlement” of the sale, even though the $1.88 billion was delivered to the FDIC after Washington Mutual’s Sept. 25, 2008, seizure. Legally, this means the deal isn’t yet done.
The most recent extension of a final settlement expires Aug. 30, 2010, according to a document obtained by shareholder Farokh Karani Lam via a Freedom of Information request. The original purchase and assumption agreement gave FDIC the right to extend the settlement “in its discretion.” The document obtained by Lam is an amendment to that original agreement.
Lam, among the shareholders who saw their shares plunge into the low singe digits in the months before the seizure and had their remaining holdings virtually wiped out, said Washington Mutual’s assets could be revalued upward and FDIC could go back to J.P. Morgan to ask for a higher price. The FDIC, he said, kept the settlement option open “to protect themselves.” Lam said his Washington Mutual shares now trade in the pennies.
But an FDIC spokesman said extensions of purchase settlements are “quite common” and “have been the rule rather than the exception” on bank seizures and sales since 2007. Such extensions, he said, are often needed as regulators and the acquiring institution work out “administrative issues” such as options on leases, contracts or branch offices. The spokesman declined comment on the possibility of going back to J.P Morgan for a higher price.
J.P. Morgan declined comment.
A lawyer representing bank bondholders said she doesn’t expect the settlement extension to result in a request for a higher price for Washington Mutual’s banking assets, as much as her clients might want that to happen. Bondholders have been fighting with the FDIC, J.P. Morgan and Washington Mutual’s bankrupt parent company over the remaining assets that belonged to the parent when the thrift was seized. A potential settlement of those claims has not yet been approved by the court.
Washington Mutual was “sold too cheap,” said Renee Dailey, a partner with Bracewell & Giuliani LLP. But “I’m not sure an extension of the settlement date means FDIC is going after a larger purchase price. I don’t think they are planning to do that at all.”
“Our clients,” she added, “think that is unfortunate.”
Copyright 2008 Dow Jones & Company, Inc. All Rights Reserved
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit
BofA, 10 Banks Facing $134 Billion in Losses on Loan Refunds, Compass Says
By David Mildenberg and Jody Shenn - Aug 18, 2010
Bank of America Corp. and JPMorgan Chase & Co. are among 11 lenders that could suffer $133.8 billion in combined losses as mortgage-bond investors and insurers demand refunds for soured loans, according to an analysis by Compass Point Research and Trading LLC.
That’s the base estimate by analyst Chris Gamaitoni, who told clients costs may range from $55.3 billion in a best-case scenario to $179.2 billion at worst. The losses would be in addition to $28 billion of buyback demands by Fannie Mae and Freddie Mac that Compass previously predicted. Deutsche Bank AG and Goldman Sachs Group Inc. are among lenders confronting the biggest potential impact, according to Gamaitoni’s report.
Lenders have been barraged by claims from mortgage buyers and insurers who say banks sold housing debt to investors based on untrue or misleading data about home loans. The estimated losses exceed 10 percent of tangible book value at eight of the banks Gamaitoni cited. While solvency isn’t at risk, the drain on profit could last for years, he said.
“The investor community overall doesn’t understand the magnitude of the problem,” Gamaitoni said in a telephone interview. Gamaitoni was a senior financial analyst at Fannie Mae before joining Compass Point, a Washington-based research and investment banking firm founded in 2007 by former executives of Friedman Billings Ramsey & Co.
Legal Claims
Bond insurers including MBIA Inc. and investors including three of the government-chartered Federal Home Loan Banks have sued securities underwriters and issuers, citing inaccurate claims over property values and quality of underlying assets. Fannie Mae and Freddie Mac collapsed into U.S. conservatorship, while MBIA saw its stock price slide more than 80 percent as losses mounted.
Bank of America, the biggest U.S. lender by assets, doesn’t comment on research reports, said Jerry Dubrowski, a spokesman for the Charlotte, North Carolina-based company. Spokesmen Michael DuVally at Goldman Sachs and JPMorgan’s Thomas Kelly declined to comment; both firms are based in New York. John Gallagher of Frankfurt-based Deutsche Bank wasn’t immediately available to comment.
Compass Point focused on the risks to underwriters of home- loan securities during the peak years of the housing boom, which included 2005 through 2007. The conclusions were based on estimates of the amount of bonds underwritten by banks backed by so-called subprime and Alt-A mortgages, which typically had the worst repayment records, plus the average default rates on the loans and a base estimate that 80 percent of defaulted loans were invalid.
Book Value
Bank of America, which acquired Countrywide Financial Corp. in 2008, faces a $35.2 billion loss under Compass Point’s base- case scenario, or 17 percent of tangible book value. JPMorgan Chase, which acquired Bear Stearns Cos. and Washington Mutual Inc., may lose $23.9 billion, or 13 percent of book value, while Deutsche Bank may lose $14.1 billion, or 21 percent of book value, according to the report. Goldman Sachs may face an $11.2 billion hit equal to 11 percent of book value, the report said.
“It’s not going to cause any solvency issues because the banks have other earnings, and it’s going to happen over time,” Gamaitoni said, estimating most of the losses will be recorded over the next three years. “It’s going to be more like a slow bleed.”
The banks, which underwrote securities made up of mortgage loans, face years of legal disputes because they are “the ones left standing” after the failure of hundreds of subprime lenders who dealt directly with home buyers, Gamaitoni said.
Legal Outlook
Underwriters typically didn’t make many contractual promises about the quality of loans in mortgage bonds, and so may be less legally liable than the companies that issued the debt or securities, according to Jonathan C. Wishnia, a lawyer at Lowenstein Sandler PC in Roseland, New Jersey, who has represented financial companies including loan servicers and investment firms.
“It seems uphill to me to go after the underwriters,” Jason H. P. Kravitt, a lawyer in New York at Mayer Brown LLP who represents clients including banks and asset-backed issuers and serves as deputy chair of the American Securitization Forum trade group, said today in a telephone interview.
To contact the reporter on this story:
David Mildenberg in Charlotte at
dmildenberg@bloomberg.net.
YRC Worldwide Establishes Strategic Relationship with Austin Ventures through the Sale of YRC Logistics
-- Completes Initial Closing with Proceeds of $33.6 Million
08/16 08:55 AM
-- YRCW Customers Will Continue to Receive Complimentary Logistic Services through Austin Ventures
OVERLAND PARK, Kan., Aug. 16, /PRNewswire-FirstCall/ -- YRC Worldwide Inc. (YRCW:$0.29,00$0.009,03.20%) today announced that it completed the initial closing on the previously announced sale of a portion of YRC Logistics. The gross proceeds for the transaction were approximately $38.7 million of which YRC Worldwide (YRCW:$0.29,00$0.009,03.20%) received $33.6 million at the initial closing with an additional $2.3 million placed in escrow for further closings of foreign entities over the coming months, and $2.8 million was placed in escrow for indemnification purposes.Â
All of the multiemployer pension funds that are parties to the company's pension contribution deferral agreement ("CDA") agreed to amend the CDA. Â The CDA amendment provides for certain terms in the company's most recent amendment to its credit agreement to be effective, including the retention of 100% of the proceeds from the sale of YRC Logistics.
YRC Worldwide (YRCW:$0.29,00$0.009,03.20%) will retain its two China-based joint ventures. The company will continue to offer its customers complimentary logistics solutions through its strategic relationship with Austin Ventures, which is created by a comprehensive commercial services agreement between the parties.
YRC Worldwide Inc. (YRCW:$0.29,00$0.009,03.20%) , a Fortune 500 company headquartered in Overland Park, Kan., is one of the largest transportation service providers in the world and the holding company for a portfolio of successful brands including YRC, YRC Reimer, YRC Glen Moore, New Penn, Holland and Reddaway. YRC Worldwide (YRCW:$0.29,00$0.009,03.20%) has the largest, most comprehensive network in North America, with local, regional, national and international capabilities. Through its team of experienced service professionals, YRC Worldwide (YRCW:$0.29,00$0.009,03.20%) offers industry-leading expertise in heavyweight shipments and flexible supply chain solutions, ensuring customers can ship industrial, commercial and retail goods with confidence. Please visit yrcw.com for more information. Â
Investor Contact:Paul LiljegrenMedia Contact:Suzanne Dawson
YRC Worldwide Inc.
Linden Alschuler & Kaplan
913.696.6108
212.329.1420
Paul.Liljegren@yrcw.com
sdawson@lakpr.com
SOURCE YRC Worldwide (YRCW:$0.29,00$0.009,03.20%)
Get more news on:SYMBOLS: YRCWNEWS TYPE: Corporate Events: Mergers and Acquisitions, Corporate EventsSECTORS: Road and Rail, Industrials
I think some groups are accumulating VSTNQ (IMHO)
Perhaps I am being simplistic, but I base this thought on an order I placed which filled today.
I had a << "Sell order for 5000 shares at a limit of 0.515 "All or None" "good for the day only">>>
It filled at the High of the day,(Showed up as a BUY in the Time and sales window" )....
Then the price went down again fractionally.
ORDER DETAIL (cut and pasted)
Stock Order: VSTNQ-VISTEON CORP COM
Status Filled at $0.515
Symbol VSTNQ
Description VISTEON CORP COM
Action Sell
Quantity 5,000 Shares
Route HUDSON SECURITIES, INC.
Order Type Limit at $0.515
Time in Force Day
Conditions All or None
Trade Type Margin
Market Session Standard
Order Date 08/10/2010, 04:05:34 PM ET
Cancel Date
Order Number H10DHDNF
EXECUTIONS FOR THIS TRADE
Date Time Price Quantity Total
08/11/2010 03:37:33 PM $0.515 5,000.000 $2,574.95
NET TOTAL 5,000.000 $2,574.95
Specified Lot Details
Let us see tomorrow...........................